What is Roth Capital’s Estimate for RNA Q3 Earnings?

Avidity Biosciences, Inc. (NASDAQ:RNA) – Research analysts at Roth Capital issued their Q3 2025 earnings per share (EPS) estimates for shares of Avidity Biosciences in a research report issued to clients and investors on Wednesday, September 17th. Roth Capital analyst B. Pachaiyappan forecasts that the biotechnology company will post earnings of ($1.02) per share for the quarter. Roth Capital currently has a “Buy” rating and a $62.00 price target on the stock. The consensus estimate for Avidity Biosciences’ current full-year earnings is ($2.89) per share. Roth Capital also issued estimates for Avidity Biosciences’ Q4 2025 earnings at ($0.96) EPS, FY2025 earnings at ($4.09) EPS, Q1 2026 earnings at ($0.98) EPS, Q2 2026 earnings at ($1.01) EPS, Q3 2026 earnings at ($1.05) EPS, Q4 2026 earnings at ($1.09) EPS and FY2026 earnings at ($4.13) EPS.

A number of other research analysts have also weighed in on RNA. Evercore ISI reissued an “outperform” rating and set a $70.00 target price on shares of Avidity Biosciences in a report on Friday, July 11th. Needham & Company LLC boosted their target price on Avidity Biosciences from $60.00 to $65.00 and gave the stock a “buy” rating in a report on Wednesday, September 10th. Wolfe Research started coverage on Avidity Biosciences in a report on Tuesday, June 17th. They set an “outperform” rating and a $55.00 target price on the stock. Wells Fargo & Company boosted their target price on Avidity Biosciences from $70.00 to $75.00 and gave the stock an “overweight” rating in a report on Friday, August 8th. Finally, Chardan Capital reissued a “buy” rating and set a $75.00 target price on shares of Avidity Biosciences in a report on Wednesday, September 10th. One equities research analyst has rated the stock with a Strong Buy rating and eighteen have given a Buy rating to the stock. According to MarketBeat.com, Avidity Biosciences has an average rating of “Buy” and an average price target of $68.58.

Avidity Biosciences Trading Down 1.8%

RNA stock opened at $41.06 on Friday. The firm has a market capitalization of $5.99 billion, a PE ratio of -11.53 and a beta of 0.99. Avidity Biosciences has a 1-year low of $21.51 and a 1-year high of $56.00. The business’s 50 day simple moving average is $41.94 and its 200 day simple moving average is $34.09.

Insider Buying and Selling

In related news, insider Teresa Mccarthy sold 10,000 shares of the firm’s stock in a transaction that occurred on Friday, August 15th. The stock was sold at an average price of $46.56, for a total transaction of $465,600.00. Following the completion of the sale, the insider owned 97,130 shares of the company’s stock, valued at $4,522,372.80. This trade represents a 9.33% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Steven George Hughes sold 2,208 shares of the firm’s stock in a transaction that occurred on Friday, August 22nd. The stock was sold at an average price of $46.40, for a total value of $102,451.20. Following the sale, the insider directly owned 38,867 shares of the company’s stock, valued at $1,803,428.80. This represents a 5.38% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 540,499 shares of company stock valued at $24,814,854. Corporate insiders own 3.83% of the company’s stock.

Institutional Investors Weigh In On Avidity Biosciences

Several large investors have recently added to or reduced their stakes in the business. Westside Investment Management Inc. acquired a new stake in Avidity Biosciences in the second quarter valued at approximately $29,000. PNC Financial Services Group Inc. grew its stake in Avidity Biosciences by 291.5% in the second quarter. PNC Financial Services Group Inc. now owns 1,476 shares of the biotechnology company’s stock valued at $42,000 after acquiring an additional 1,099 shares during the period. Osaic Holdings Inc. grew its stake in Avidity Biosciences by 1,659.1% in the second quarter. Osaic Holdings Inc. now owns 1,636 shares of the biotechnology company’s stock valued at $48,000 after acquiring an additional 1,543 shares during the period. Parallel Advisors LLC grew its stake in Avidity Biosciences by 43.3% in the first quarter. Parallel Advisors LLC now owns 1,705 shares of the biotechnology company’s stock valued at $50,000 after acquiring an additional 515 shares during the period. Finally, Elevation Point Wealth Partners LLC acquired a new stake in Avidity Biosciences in the second quarter valued at approximately $49,000.

About Avidity Biosciences

Avidity Biosciences, Inc, a biopharmaceutical company, engages in the delivery of RNA therapeutics. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat diseases previously untreatable with RNA therapeutics. The company's lead product candidate AOC 1001 for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease that is in phase 1/2 clinical trial.